Roche lung cancer hopeful wins FDA 'breakthrough' tag

Roche ($RHHBY) nabbed another breakthrough therapy designation for its lung cancer drug alectinib, to be featured at the European Cancer Congress in Amsterdam later this month. That makes two "breakthrough" tags for the Swiss drugmaker so far. Report 

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.